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Editorial
Imatinib as a novel therapeutic approach for fibrotic disorders
Imatinib mesylate is a small molecule that binds to the ATP-
binding pocket of Abelson kinase (c-Abl) and blocks efficiently
its tyrosine kinase activity. c-Abl is an important downstream
signalling molecule of TGF- [1]. The importance of c-Abl for the
pro-fibrotic effects of TGF- is emphasized by the observation
that the induction of extracellular matrix proteins by TGF- is
strongly decreased in cells deficient for c-Abl. In addition to its
effects on c-Abl, imatinib blocks the tyrosine kinase activity of
PDGF receptors. Thus, imatinib targets simultaneously and
also rather selectively TGF- and PDGF signalling, two major
pro-fibrotic pathways in SSc [2].
Imatinib is widely used for the treatment of bcr-Abl-positive
chronic myelogenous leukaemia (CML) and gastrointestinal
stromal tumours with more than 100 000 patients treated so far.
Imatinib possesses favourable pharmacokinetics: (i) it is readily
absorbed after oral administration; (ii) one dose per day is
sufficient, because of the long half-life of imatinib [2]. Imatinib is
generally well tolerated and severe adverse effects are rare.
However, less severe side-effects are common and might lead
to discontinuation in 15–30% of the patients outside of clinical
trials [3]. The major adverse events of imatinib are often dose-
dependent and include oedema, muscle cramps, diarrhoea and
bone marrow toxicity [3, 4]. Abl-kinase inhibitors might also
increase slightly the risk of congestive heart failure [5, 6].
Pre-clinical evidence for the anti-fibrotic effects of imatinib
We demonstrated that imatinib inhibited dose-dependently the
synthesis of collagen 1a1, collagen 1a2 and fibronectin-1 of SSc
fibroblasts by up to 90% in pharmacologically relevant concen-
trations [7]. No compensatory changes of the expression of tissue
inhibitors of matrix metalloproteinases (TIMPs) and MMPs were
observed. Furthermore, imatinib efficiently reduced the develop-
ment of fibrosis in the mouse model of bleomycin-induced dermal
fibrosis. Treatment of mice with imatinib at doses of 50mg/kg/day
and 150mg/kg/day had strong anti-fibrotic effects. Imatinib
prevented the differentiation of resting fibroblasts into myofibro-
blasts and reduced dose-dependently the synthesis and accumula-
tion of extracellular matrix in lesional skin.
Apart from SSc, imatinib has also been shown to be effective in
models of pulmonary fibrosis, renal fibrosis and liver fibrosis
[1, 8–10]. In all of these models, imatinib prevented the develop-
ment of fibrosis, when initiated at the onset of the fibrotic
stimulus.
We demonstrated recently that imatinib can also induce
regression of pre-existing dermal fibrosis. To evaluate the efficacy
of imatinib for established fibrosis, a modified model of
bleomycin-induced fibrosis was used. In this model, mice were
challenged with imatinib for 6 weeks and subgroups of mice were
additionally treated with imatinib for the past 3 weeks. Treatment
with imatinib not only prevented further progression of dermal
fibrosis despite ongoing injections of bleomycin, but also induced
regression of fibrosis below the levels of mice challenged with
bleomycin for 3 weeks [11].
We also showed that dasatinib and nilotinib, two novel and
more potent inhibitors of Abl-kinases, and PDGF receptors,
which are approved for the treatment of Bcr-Abl-positive chronic
myelogenous leukaemia with resistance or intolerance to imatinib,
also have potent anti-fibrotic effects in vitro and in vivo [2]. As the
spectra of adverse effects of dasatinib and nilotinib differ from
that of imatinib, patients with intolerance to imatinib can often
be switched safely to nilotinib or dasatinib. Thus, dasatinib and
nilotinib might be interesting candidates for the treatment of
patients that cannot tolerate imatinib.
Clinical outcome of first patients with fibrotic diseases
Sabnani and coworkers [12] report in this issue of Rheumatology
five patients with SSc-related interstitial lung disease (SSc-ILD)
treated with a combination of imatinib and cyclophosphamide.
All but one patient had severe, end-stage SSc-ILD with a <25%
predicted diffuse capacity for carbon monoxide (DLCO). The
forced vital capacity (FVC) was <50% predicted in three patients
and three patients were too ill to perform a 6-min walking test.
All patients had previously received immunosuppressants, includ-
ing oral cyclophosphamide in three patients. Thus, the patients
reported by Sabnani et al. were critically ill with end-stage disease
that had been progressive despite several therapeutic attempts.
These patients were treated with intravenous pulses of 500mg
cyclophosphamide every 3 weeks and oral imatinib in various
doses. One patient received 100mg, two received 200mg and two
patients started with 200mg for 6 months and then received
400mg. The follow-up time and the duration of the treatment
were different for the five patients and ranged from 3 to
18 months.
Imatinib was well tolerated by all patients and major treatment-
related adverse effects did not occur. In particular, none of the
patients developed clinical evidence of congestive heart failure,
although echocardiography or repeated heart catheterization was
not performed. Fluid retention was mild and required diuretics in
only one patient. Three patients showed mild reductions in
haemoglobin levels and erythropoietic stimulating agents were
given.
The outcome of the patients was different. One patient, who
was suffering from severe other comorbidities, such as left
ventricular dysfunction, died within 3 months before the first
follow-up. In one patient, the DLCO remained stable, but FVC
and total lung capacity (TLC) decreased slightly and the patient
underwent lung transplantation after 6 months. One patient, who
had the worst lung function parameters initially, died after 12
months of therapy. Within this period, his DLCO, FVC and TLC
remained stable. Improvement was observed in two patients. One
patient experienced a mild increase in all lung function para-
meters. The other patient improved by 26% in DLCO, but not in
FVC and TLC. Additional information on morphological changes
on high-resolution computed tomography (HRCT), changes in
6-min walking distance, New York Heart Association (NYHA)
classification, Borg dyspnoea index, scleroderma HAQ (SHAQ)
or arterial oxygen saturation were not mentioned.
When interpreting the results of this study, one has to keep in
mind that imatinib was underdosed in this study. All patients
received only 100 or 200mg of imatinib for the first 6 months. The
doses of imatinib for the treatment of CML and gastrointestinal
stromal tumours (GIST) range from 400mg/day to 800mg/day.
Although the number of patients was small and this might have
been by chance, it is striking that the two patients, who improved
during treatment, received imatinib in normal doses of 400mg/day
during the second half of the study. Thus, the doses of imatinib
might have been subtherapeutic and imatinib might exert more
potent anti-fibrotic effects in standard doses. However, most
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adverse events of imatinib are dose dependent, and thus the rate of
adverse effects might increase with higher doses of imatinib.
Another interesting observation is that two of the three patients,
who had previously been unresponsive to treatment with
cyclophosphamide alone, improved moderately under the combi-
nation of cyclophosphamide plus low-dose imatinib.
There is also preliminary clinical evidence from other case
reports that imatinib appears to be safe and could be efficacious in
fibrotic CTDs. We reported recently the successful treatment of
pulmonary fibrosis with imatinib in a patient with MCTD [13].
Before initiation of imatinib, the patient rapidly deteriorated
despite treatment with corticosteroids and MTX. However, during
the 20 weeks of treatment with imatinib at a dose of 400mg/day,
the patient progressively improved. The NYHA class changed
from NYHA IV to NYHA II. The 6-min walking distance
increased by 50m and the DLCO increased from 26% predicted to
45% predicted. The arterial oxygen pressure increased from
64mmHg to 70mmHg at rest and from 50mmHg to 62mmHg
after exertion. Ground glass opacities decreased during treatment,
whereas the reticular changes remained constant. However, no
changes in FVC and TLC were observed. The patient tolerated
the treatment well and did not experience any adverse events.
Van Daele et al. [14] reported stabilization of pulmonary
fibrosis and improvement of dermal fibrosis in a patient with
refractory SSc. Prior to imatinib, the patient experienced prog-
ressive dermal and pulmonary fibrosis with increasing honey-
combing on HRCT despite treatment with corticosteroids and
pulsed cyclophosphamide. Upon initiation of imatinib at a
dose of 400mg/day, her modified Rodnan skin score (mRSS)
dropped from 18 to 12 within the first 3 months and remained
stable thereafter. Pulmonary function test and findings on HRCT
remained stable during the 7 months of treatment with imatinib.
Imatinib was well tolerated with only mild periorbital oedema.
Sfikakis and coworkers [15] also reported beneficial effects
of imatinib for the treatment of refractory SSc. The patient had
severe diffuse SSc with 7-yr duration and had previously been
treated with cyclophosphamide, AZA and mycophenolate mofetil.
The mRSS before treatment with imatinib was 44. During the
6-month course with imatinib at a dose of 400mg/day, the mRSS
decreased progressively to 33 after 6 weeks and to 28 after
3 months and 6 months. In parallel, contractions decreased
and the SHAQ score improved.
Kay and High [16] reported recently impressive responses
of two patients with nephrogenic systemic fibrosis. Both patients
were treated with imatinib in doses of 400mg/day. In the first
patient, the mRSS decreased from 42 to 16 within 15 weeks. In the
second patient, a decrease from 12 to 2 occurred within 12 weeks.
In parallel to the mRSS, reduced fibrosis and decreased expression
of Type I procollagen was observed in skin biopsies of imatinib-
treated patients. Of note, skin thickening rapidly recurred in both
patients within a few weeks after imatinib was stopped, probably
because of the persistent accumulation of gadolinium. However,
both patients responded again, when imatinib was re-introduced.
Smaller case series suggested that treatment of patients with
CML might lead to a regression of concomitant bone marrow
fibrosis [17, 18]. The anti-fibrotic effect did not correlate with the
cytogenetic response, suggesting an effect independent from the
suppression of Philadelphia chromosome-positive cancer cells [18].
Conclusions
Due to the potent anti-fibrotic effects in vitro and in vivo in several
pre-clinical animal models of tissue fibrosis, favourable pharma-
cokinetics, good clinical experience regarding safety and toxicity
in other diseases and first promising case reports, imatinib is
currently investigated in clinical trials as an anti-fibrotic drug
for the treatment of SSc. However, one needs to be cautious in
over-interpreting the results of the first case series. The course of
SSc is variable with spontaneous regression of dermal fibrosis in
several patients. Thus, it cannot be excluded that the regression of
fibrosis reported in the mentioned case reports might reflect the
spontaneous course of the disease in individual patients and not
a response to imatinib. Regarding safety, appropriate outcome
measures in particular for cardiotoxicity are necessary in a larger
number of patients to exclude relevant side-effects in the SSc
population. This is of importance, because the large majority of
SSc patients have pre-existing cardiac pathologies, although
this rarely manifests clinically. In addition, gastrointestinal side
effects might be more frequent in SSc patients because of the
gastrointestinal involvement in SSc.
Therefore no definite conclusions regarding safety and efficacy
can be drawn from the published case reports. The safety and
efficacy of imatinib can only be investigated in larger controlled
clinical trials. For these reasons we strongly recommend inclusion
of patients with SSc into one of the ongoing clinical trials with
imatinib (see www.clinicaltrials.gov for details). We discourage
the off-label use of imatinib for routine use in such patients, as
long as the toxicity profile in SSc patients is not established and as
long as results of the ongoing clinical trials are not available.
Moreover, the off-label use of imatinib is limited by the high costs
that exceed that of other biologics.
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